Scarica l'app Stockscreener
3.60
2.23%
0.01
Precedente Chiudi:
$3.59
Aprire:
$3.74
Volume 24 ore:
5,545
Relative Volume:
0.07
Capitalizzazione di mercato:
$33.54M
Reddito:
-
Utile/perdita netta:
$-19.09M
Rapporto P/E:
-2.0225
EPS:
-1.78
Flusso di cassa netto:
$-17.24M
1 W Prestazione:
+18.01%
1M Prestazione:
+3.38%
6M Prestazione:
+0.27%
1 anno Prestazione:
-33.27%
Intervallo 1D:
$3.54
$3.86
Intervallo di 1 settimana:
$3.07
$3.93
Portata 52W:
$2.55
$7.21
Lantern Pharma Inc Stock (LTRN) Company Profile
Nome
Lantern Pharma Inc
Settore
Industria
Telefono
972-277-1136
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Confronta LTRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.5526 | 33.54M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.99 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.10 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
616.09 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.18 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
251.61 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-07 | Iniziato | H.C. Wainwright | Buy |
Lantern Pharma Inc Borsa (LTRN) Ultime notizie
Press Release Distribution & PR Platform - ACCESS Newswire
Lantern Pharma stock hits 52-week low at $2.77 amid market challenges - Investing.com Australia
Lantern Pharma stock hits 52-week low at $2.77 amid market challenges By Investing.com - Investing.com South Africa
Lantern Pharma : Announces Upcoming Conference Presentations - MarketScreener
Lantern Pharma (NASDAQ:LTRN) Research Coverage Started at Lake Street Capital - The AM Reporter
Lake Street Capital Begins Coverage on Lantern Pharma (NASDAQ:LTRN) - Defense World
Lake Street Initiates Coverage of Lantern Pharma (LTRN) with Buy Recommendation - Nasdaq
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navi - GuruFocus
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges By GuruFocus - Investing.com Canada
Lantern Pharma outlines 2025 clinical milestones and key updates on oncology trials - MSN
Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2024 Earnings Call Transcript - Insider Monkey
Lantern Pharma’s Earnings Call: AI Advances Amid Financial Challenges - TipRanks
Lantern Pharma Advances AI-Driven Oncology Pipeline - TipRanks
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results - 01net
LANTERN PHARMA Earnings Results: $LTRN Reports Quarterly Earnings - Nasdaq
Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses - Investing.com India
Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses By Investing.com - Investing.com South Africa
Lantern Pharma Inc (LTRN) Reports Q4 EPS of -$0.51, Aligning wit - GuruFocus
Lantern Pharma Inc Qtrly EPS $-0.54 - MarketScreener
Lantern Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lantern Pharma Reports Q4 2024 Financial Results and AI Progress - TipRanks
Earnings Scheduled For March 27, 2025 - Benzinga
Preview: Lantern Pharma's Earnings - Benzinga
Lantern Pharma Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - BioSpace
Lantern Pharma's AI Platform Breakthrough: Q4 Results and Clinical Trial Milestones Revealed - Stock Titan
LTRN: M&A Illuminates GBM Value - Yahoo Finance
Lantern Pharma (LTRN) Expected to Announce Earnings on Monday - Defense World
Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World
Sanctuary Advisors LLC Purchases New Holdings in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech - Insider Monkey
Lantern Pharma advances AI-driven drug development with patent - Investing.com India
Lantern Pharma advances AI-driven drug development with patent By Investing.com - Investing.com Nigeria
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates - Business Wire
Perigon Wealth Management LLC Decreases Stake in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma (NASDAQ:LTRN) Stock Price Down 15% – Here’s What Happened - Defense World
Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies - Yahoo Finance
Top 10 AI Stocks Dominating Wall Street - Insider Monkey
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer - BioSpace
Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Insider Monkey
Lantern Pharma Inc Azioni (LTRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lantern Pharma Inc Azioni (LTRN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fletcher Aaron G.L. | 10% Owner |
May 23 '24 |
Sale |
6.25 |
10,000 |
62,500 |
59,326 |
0.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):